

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH

23149

DEPARTMENT OF FOOD AND DRUG ADMINISTRATION

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub-section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name ViiV Healthcare UK Limited

Address 980, Great West Road, Brentford, Middlesex, TW8 9 GS, UK

Name of product APRETUDE 600MG

Manufacturer Glaxo Operations UK Ltd. (trading as Glaxo Wellcome Operations), Durham, UK

Dosage form Prolonged – Release Suspension for Injection

Presentation One clear glass vial in a carton box

Therapeutic Category Antiretroviral

Strength & Composition Each vial contains: 600mg Cabotegravir in 3ml

Sales Category Prescription Only Medicine

This certificate shall be valid until June, 2029 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without approval of Department of Food and Drug Administration, Myanmar.

Ref: (3/2024)

Registration No 2906AA6004

Date of issue 26th June, 2024

Signature  11.9.2024

Name Professor Dr. Khin Zaw

Designation Director General